273 related articles for article (PubMed ID: 25797071)
1. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
[TBL] [Abstract][Full Text] [Related]
2. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Li F; Xia W; Yuan S; Sun R
Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
[TBL] [Abstract][Full Text] [Related]
3. [Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
Ruan HY; Zhang YG; Liu R
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(9):678-681. PubMed ID: 29534403
[No Abstract] [Full Text] [Related]
4. Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension.
Odagiri K; Watanabe H
Circ J; 2015; 79(6):1213-4. PubMed ID: 25925979
[No Abstract] [Full Text] [Related]
5. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Ruan H; Zhang Y; Liu R; Yang X
Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
[TBL] [Abstract][Full Text] [Related]
6. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
[TBL] [Abstract][Full Text] [Related]
7. Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension.
Zhang DZ; Zhu XY; Meng J; Xue HM; Sheng XT; Han XM; Cui CS; Wang QG; Zhang P
Int J Cardiol; 2011 Mar; 147(3):433-7. PubMed ID: 20537740
[TBL] [Abstract][Full Text] [Related]
8. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
Jiang X; Wang YF; Zhao QH; Jiang R; Wu Y; Peng FH; Xu XQ; Wang L; He J; Jing ZC
Int J Cardiol; 2014 Nov; 177(1):61-5. PubMed ID: 25499341
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Li FH; Xia W; Li AW; Zhao CF; Sun RP
Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
[TBL] [Abstract][Full Text] [Related]
11. Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects.
Li Q; Dimopoulos K; Zhang C; Zhu Y; Liu Q; Gu H
Pediatr Cardiol; 2018 Apr; 39(4):757-762. PubMed ID: 29426959
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
Fukumoto Y; Yamada N; Matsubara H; Mizoguchi M; Uchino K; Yao A; Kihara Y; Kawano M; Watanabe H; Takeda Y; Adachi T; Osanai S; Tanabe N; Inoue T; Kubo A; Ota Y; Fukuda K; Nakano T; Shimokawa H
Circ J; 2013; 77(10):2619-25. PubMed ID: 23912836
[TBL] [Abstract][Full Text] [Related]
13. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
14. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.
Zhang X; Zhang X; Wang S; Luo J; Zhao Z; Zheng C; Shen J
Can Respir J; 2018; 2018():3148259. PubMed ID: 29785232
[TBL] [Abstract][Full Text] [Related]
15. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Gupta N; Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Mol Pharm; 2017 Mar; 14(3):830-841. PubMed ID: 28165252
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.
Latus H; Wagner I; Ostermayer S; Kerst G; Kreuder J; Schranz D; Apitz C
Pediatr Cardiol; 2017 Oct; 38(7):1342-1349. PubMed ID: 28681131
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
18. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
19. The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis.
Abedi F; Omidkhoda N; Arasteh O; Ghavami V; Hosseinzadeh H
Drug Res (Stuttg); 2023 Jan; 73(1):5-16. PubMed ID: 36216340
[TBL] [Abstract][Full Text] [Related]
20. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Badejo AM; Dhaliwal JS; Casey DB; Gallen TB; Greco AJ; Kadowitz PJ
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L828-36. PubMed ID: 18689606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
